At 15y analyses, extended ET did not show an OS benefit. Now both adjuvant abema and ribo have positive OS results. Do you think there is still a role for extending ET after adjuvant CDK4/6i?
#ESMO26 #ESMOAmbassadors @myESMO
835 浏览 · 4 赞 · 1 转发 · 5 回复
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- Michiel Strijbos@StrijbosMichiel
@Rodrosb @myESMO Where did you see the ribo OS benefit???
- Gabriel Lazcano@gv_lazcano
@Rodrosb @myESMO Wrong question, as CDK4/6i shouldn't be considered SoC for adjuvancy. I'm gonna die on that hill. Let's no justify financial toxicity based on marginal benefits and forced p-values. Our patients deserve better.
- Pablo Jara Martin@pablojaramartin
@Rodrosb @myESMO I see the benefit in high-risk, node-positive patients, especially after the NSABP B-42 data presented at #ESMO26. However, I have more doubts about the N0 population in NATALEE. Great topic!@Rodrosb
- Paula Cabrera@anelcabrera
@Rodrosb @myESMO And what if the control arm of CDK4-6i is not the best??
- Rodrigo Sánchez-Bayona@Rodrosb
@anelcabrera @PabloMando @matteolambe @E_de_Azambuja @PTarantinoMD
来源：Rodrigo Sánchez-Bayona · x.com